Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 17, 2023
Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adultsJia Yao Phuah, Brian M Maas, Aimin Tang, et al.The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.Journal of Gastroenterology and Hepatology|February 20, 2019
Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infectionLai Wei, Hiromitsu Kumada, Ponni V Perumalswami, et al.Clinical Pharmacology in Drug Development|October 30, 2020
A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK-1654 in Healthy AdultsAntonios O Aliprantis, Dennis Wolford, Luzelena Caro, et al.Journal of Gastroenterology|November 23, 2016
The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III studyHiromitsu Kumada, Yoshiyuki Suzuki, Yoshiyasu Karino, et al.Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.Antiviral Research|June 11, 2013
Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokineticsEric Lawitz, Mark Sulkowski, Ira Jacobson, et al.Pageof 6